GeoVax Labs, Inc. has announced a new research program to evaluate the GEO-MVA vaccine's delivery through Vaxxas' high-density microarray patch (HD-MAP) technology. This study, conducted at the University of Queensland, aims to assess the vaccine's immunogenicity, delivery efficiency, and thermostability when administered via HD-MAPs in mice. The HD-MAP technology promises a needle-free, skin-targeted delivery method that could improve immunogenicity and eliminate the need for refrigeration, making vaccines more accessible worldwide.
David Dodd, GeoVax's Chairman and CEO, highlighted the program's potential to revolutionize vaccine delivery by enabling self-administration, increasing patient acceptance, and reducing reliance on cold chain logistics. Successful outcomes could lead to the development of a thermostable, needle-free vaccine platform, crucial for pandemic response and immunization programs in low- and middle-income countries.
The Vaxxas HD-MAP platform has shown promise in enhancing immunogenicity in previous studies, offering advantages such as dose-sparing, elimination of sharps waste, and faster deployment in emergencies. GeoVax's initiative aligns with global needs for more accessible and effective vaccination methods, supported by favorable regulatory feedback from the European Medicines Agency for the GEO-MVA vaccine's development pathway.
